The numbers add up with even conservative simple math!
Most Cancer cases form at the age of 60 with millions of baby boomers coming to that age and using 1 out of every ten would require cancer treatment + the current cost of Cancer Treatment for the world at 1 Trillion = A 10 Trillion Dollar Global Economic Bomb. Backed up with facts.
The World Health Organization estimates cancer treatments cost more than One-
It has been estimated that more than 1 in 3 people (33%) will develop cancer at some point in their lifetime. Cancers can occur at any age, but the risk of developing cancer increases with age. Cancer isn’t common in children or young people.
- Three-quarters (75%) of all newly diagnosed cancers occur in people aged 60 or over.
- Less than 1 in 100 (1%) of cancers are diagnosed in children, aged 14 years or under.
- About 1 in 10 (10%) of cancers are diagnosed in people aged 25-49.
In the United States, approximately 14 million people have had cancer and more than 1.6 million new cases are diagnosed each year.
However, more than a decade after the Institute of Medicine (IOM) first studied the quality of cancer care, the barriers to achieving excellent care for all cancer patients remain daunting. Care often is not patient-centered, many patients do not receive palliative care to manage their symptoms and side effects from treatment, and decisions about care often are not based on the latest scientific evidence.
This lecture presents a conceptual framework for improving the quality of cancer care for cancer care teams, patients, and their families, researchers, and insurance companies.
Patricia A. Ganz, M.D. is the Director, Cancer Prevention & Control Research at the David Geffen School of Medicine at UCLA. Published on May 9, 2014
Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis
Need More Facts on The Need for Cancer Treatment Overhaul – A 10 Trillion Dollar Bomb
The pace of annual global spending on oncology medicines only is approaching the $100 billion thresholds, this has somewhat stabilized over the past five years, even as a surge in innovative and targeted therapies has brought new therapeutic options to the growing number of patients being treated for cancer. The survival rates for most tumor types continue to get better.
Growth in global spending on cancer drugs, including those used for supportive care, increased at a compound annual growth rate of 5.4 percent during the past five years, reaching $91 billion in 2013, compared with 14.2 percent from 2003 to 2008. The recent lower growth rate reflects fewer breakthrough therapies for very large patient populations.
There have been reductions in the use of supportive care medicines, and stronger payer management.
While oncology spending remains concentrated among the U.S. and five largest European countries – which together account for 65 percent of the total market.
Targeted therapies have dramatically increased their share of global oncology sales, from 11 percent a decade ago to 46 percent last year. Payers have intensified their scrutiny of the value of these medicines relative to their incremental benefits over existing treatments. At the same time, the average cost per month for a branded oncology drug in the U.S. is now approximately $10,000, up from an average of $5,000 a decade ago.
“As the cancer patient population mix shifts from mature and developed markets to low – and middle-income countries, oncology is bringing higher levels of uncertainty to health systems across the globe – both in terms of the nature and rate of innovative treatments, and levels of reimbursement for patient care,” said Murray Aitken, IMS Health senior vice president and executive director of the IMS Institute for Healthcare Informatics. “While an estimated 30 percent of cancers are preventable and early diagnosis and treatment can reduce or delay mortality significantly, the reality is that countries struggle to bring together the right combination of preventive measures and clinical interventions, including vaccines, diagnostics, and therapeutics.”